problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201157413-16problendo-4568Research ArticleСтатьиArticlesРоль пептида YY3-36 в регуляции массы тела у больных с экзогенно-конституциональной формой ожиренияThe role of YY3-36 peptide in the regulation of body weight in patients presenting with the exogenous constitutional form of obesityVlasovaIu Iu-AmetovA S-201115082011574ТОМ 57, №4 (2011)1316Copyright © Vlasova I.I., Ametov A.S., 20112011Vlasova I.I., Ametov A.S.Vlasova I.I., Ametov A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4568

Изучали уровень общего пептида YY3-36 в сыворотке больных с экзогенно-конституциональной формой ожирения и избыточной массой тела, а также его влияния на процесс увеличения массы тела. Обследовали 327 лиц с ожирением и избыточной массой тела. Повышенные уровни общего пептида YY3-36 выявлены у пациентов с I, II степенями ожирения. Наиболее высоким уровень пептида YY3-36 оказался у лиц со II степенью ожирения. Экзогенно-конституциональная форма ожирения I и II степени сопровождается статистически значимым повышением уровня общего пептида YY3-36.

The objective of the present study was to measure the total YY3-36 peptide levels in blood sera obtained from the patients presenting with the exogenous constitutional form of obesity and excessive body weight. The secondary objective was to elucidate the influence of YY3-36 peptide on the process of body weight elevation. A significant rise in the serum YY3-36 peptide level was documented in those of the 327 patients included in the study who suffered grade I and II obesity (p<0,05). It was especially high in the patients with grade II obesity (p<0,05). It is concluded that the exogenous constitutional form of obesity is associated with a statistically significant elevation of blood YY3-36 peptide level in patients presenting with grade I and II obesity.

ожирениепептид YY3-36obesityYY3-36 peptideReferencesSchwartz M.W., Woods S.C., Porte D. Jr. et al. Central nervous system control of food intake. Nature 2000; 404: 6778: 661-671.Schwartz M.W., Woods S.C., Porte D. Jr. et al. Central nervous system control of food intake. Nature 2000; 404: 6778: 661-671.Konturek P.C., Konturek J.W., Cześnikiewicz-Guzik M. et al. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J Physiol Pharmacol 2005; 56: Suppl 6: 5-25.Konturek P.C., Konturek J.W., Cześnikiewicz-Guzik M. et al. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J Physiol Pharmacol 2005; 56: Suppl 6: 5-25.Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004; 145: 6: 2613-2620.Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004; 145: 6: 2613-2620.Batterham R.L., Cowley M.A., Small C.J. et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 6898: 650-654.Batterham R.L., Cowley M.A., Small C.J. et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 6898: 650-654.Tatemoto K., Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 5764: 417-418.Tatemoto K., Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 5764: 417-418.Batterham R.L., Cohen M.A., Ellis S.M. et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 10: 941-948.Batterham R.L., Cohen M.A., Ellis S.M. et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 10: 941-948.Grandt D., Schimiczek M., Beglinger C. et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 1994; 51: 2: 151-159.Grandt D., Schimiczek M., Beglinger C. et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 1994; 51: 2: 151-159.Frayn K.N. Metabolic regulation. A human perspective. Blackwel Publisching Company. Oxford United Kingdom 2003; 441-446.Frayn K.N. Metabolic regulation. A human perspective. Blackwel Publisching Company. Oxford United Kingdom 2003; 441-446.Helou N., Obeid O., Azar S.T. et al. Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females. Ann Nutr Metab 2008; 52: 3: 188-195.Helou N., Obeid O., Azar S.T. et al. Variation of postprandial PYY 3-36 response following ingestion of differing macronutrient meals in obese females. Ann Nutr Metab 2008; 52: 3: 188-195.Беляков Н.А., Мазурова В.И. Ожирение. Руководство для врачей. Ст-Петербург 2003; 8-9.Беляков Н.А., Мазурова В.И. Ожирение. Руководство для врачей. Ст-Петербург 2003; 8-9.Viardot A., Heilbronn L.K., Herzog H. et al. Abnormal postprandial PYY response in insulin sensitive nondiabetic subjects with a strong family history of type 2 diabetes. Int J Оbes 2008; 32: 6: 943-948.Viardot A., Heilbronn L.K., Herzog H. et al. Abnormal postprandial PYY response in insulin sensitive nondiabetic subjects with a strong family history of type 2 diabetes. Int J Оbes 2008; 32: 6: 943-948.Xu J., McNearney T.A., Chen J. Impaired postprandial releases/syntheses of ghrelin and PYY(3-36) and blunted responses to exogenous ghrelin and PYY(3-36) in a rodent model of diet-induced obesity. J Gastroenterol Hepatol 2011; 26: 4: 700-705.Xu J., McNearney T.A., Chen J. Impaired postprandial releases/syntheses of ghrelin and PYY(3-36) and blunted responses to exogenous ghrelin and PYY(3-36) in a rodent model of diet-induced obesity. J Gastroenterol Hepatol 2011; 26: 4: 700-705.Dalia El Khoury D., Rola El-Rassi R., Azar S., Hwalla N. Postprandial grelin and PYY responses of male subjects on low carbohydrate meals to varied balancing proportions of proteins and fats. Eur J Nutr 2010; 49: 8: 493-500.Dalia El Khoury D., Rola El-Rassi R., Azar S., Hwalla N. Postprandial grelin and PYY responses of male subjects on low carbohydrate meals to varied balancing proportions of proteins and fats. Eur J Nutr 2010; 49: 8: 493-500.Everitt B.J., Hokfelt T., Terenius L. et al. Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience 1984; 11: 2: 443-462.Everitt B.J., Hokfelt T., Terenius L. et al. Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience 1984; 11: 2: 443-462.Harfstrand A., Eneroth P., Agnati L., Fuxe K. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Regul Pept 1987; 17: 3: 167-179.Harfstrand A., Eneroth P., Agnati L., Fuxe K. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Regul Pept 1987; 17: 3: 167-179.Kubota Y., Inagaki S., Kito S. et al. Neuropeptide Y-immunoreactive neurons receive synaptic inputs from dopaminergic axon terminals in the rat neostriatum. Brain Res 1988; 458: 2: 389-393.Kubota Y., Inagaki S., Kito S. et al. Neuropeptide Y-immunoreactive neurons receive synaptic inputs from dopaminergic axon terminals in the rat neostriatum. Brain Res 1988; 458: 2: 389-393.Sahu A., Kalra S.P., Crowley W.R., Kalra P.S. Evidence that NPY-containing neurons in the brainstem project into selected hypothalamic nuclei: implication in feeding behavior. Brain Res 1988; 457: 2: 376-378.Sahu A., Kalra S.P., Crowley W.R., Kalra P.S. Evidence that NPY-containing neurons in the brainstem project into selected hypothalamic nuclei: implication in feeding behavior. Brain Res 1988; 457: 2: 376-378.Boey D., Lin S., Karl T. et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006; 49: 6: 1360-1370.Boey D., Lin S., Karl T. et al. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 2006; 49: 6: 1360-1370.

The authors declare that there are no conflicts of interest present.